J Korean Ophthalmol Soc.  2017 Sep;58(9):1080-1086. 10.3341/jkos.2017.58.9.1080.

Efficacy of Primary Intravitreal Ranibizumab Injection for Treatment of Type 1 Retinopathy of Prematurity

• Chung GC
• Moon SH

• KMID: 2390072
• DOI: http://doi.org/10.3341/jkos.2017.58.9.1080

Abstract

PURPOSE
To evaluate the effectiveness and safety of primary intravitreal ranibizumab injection as a treatment for retinopathy of prematurity.
METHODS
Retrospective analysis of the medical records of patients diagnosed with retinopathy of prematurity and treated with intravitreal ranibizumab injection from January 1, 2013 to January 1, 2016 was performed. We complied with the standards for "˜prethresold, type 1' established by the Early Treatment of Retinopathy of Prematurity study for intravitreal ranibizumab injection. The follow-up period after injection was at least 9 months. Patients who received additional treatment such as laser photocoagulation or intravitreal injection without reactivation of retinopathy of prematurity were excluded.
RESULTS
A total of 21 patients (39 eyes) were included in this study. Nine (16 eyes) were male and 12 (23 eyes) were female. The average duration between treatment decision and intravitreal ranibizumab injection was 2.1 ± 1.5 days. Complete regression of the plus sign occurred 18.2 ± 9.1days after injection. One eye with reactivation was treated with panretinal laser photocoagulation while four other eyes with reactivation were treated with intravitreal bevacizumab injection. There were 87.1% (34/39) eyes that underwent primary intravitreal ranibizumab injection with stable results without any reactivation. There were no systemic complications related to intravitreal ranibizumab injection.
CONCLUSIONS
Primary intravitreal ranibizumab injection as a treatment for retinopathy of prematurity showed good efficacy and safety. However, thorough evaluation is needed after primary intravitreal ranibizumab injection due to the potential for reactivation. Long-term monitoring is needed after intravitreal ranibizumab injection.

Keyword

Intravitreal injection; Ranibizumab; Retinopathy of prematurity; Type 1

MeSH Terms

Bevacizumab
Female
Follow-Up Studies
Humans
Intravitreal Injections
Light Coagulation
Male
Medical Records
Ranibizumab*
Retinopathy of Prematurity*
Retrospective Studies
Bevacizumab
Ranibizumab

Reference

References

1. Hartnett ME, Penn JS. Mechanisms and management of retinop-athy of prematurity. N Engl J Med. 2012; 367:2515–26.

2. Hellström A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet. 2013; 382:1445–57.

3. Sapieha P, Joyal JS, Rivera JC. . Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J Clin Invest. 2010; 120:3022–32.

4. Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of pre-maturity: results of the early treatment for retinopathy of pre-maturity randomized trial. Arch Ophthalmol. 2003; 121:1684–94.

5. Good WV, Hardy RJ, Dobson V. . The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics. 2005; 116:15–23.

6. Mintz-Hittner HA, Kennedy KA, Chuang AZ. BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011; 364:603–15.

7. Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photo-coagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2007; 245:1727–30.

8. Lee JY, Chae JB, Yang SJ. . Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol. 2010; 248:1257–62.

9. Harder BC, Baltz S, Jonas JB, Schlichtenbrede FC. Intravitreal low ‐dosage bevacizumab for retinopathy of prematurity. Acta oph-thalmol. 2014; 92:577–81.

10. Sato T, Wada K, Arahori H. . Serum concentrations of bev-acizumab (avastin) and vascular endothelial growth factor in in-fants with retinopathy of prematurity. Am J Ophthalmol. 2012; 153:327–33.e1.

11. Castellanos MA, Schwartz S, García-Aguirre G, Quiroz-Mercado H. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol. 2013; 97:816–9.

12. Baumal CR, Goldberg RA, Fein JG. Primary intravitreal ranibizu-mab for high-risk retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina. 2015; 46:432–8.

13. Chen SN, Lian I, Hwang YC. . Intravitreal anti-vascular endo-thelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina. 2015; 35:667–74.

14. Hu J, Blair MP, Shapiro MJ. . Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012; 130:1000–6.

15. Fierson WM; American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology. . Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013; 131:189–95.

16. Wong RK, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015; 35:675–80.

17. Erol MK, Coban DT, Sari ES. . Comparison of intravitreal rani-bizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol. 2015; 78:340–3.

18. Kim SE, Rim TH, Lee CS. Effect of primary intravitreal bev-acizumab injection on stage 3 retinopathy of prematurity with plus signs. J Korean Ophthalmol Soc. 2015; 56:62–9.

19. Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical manage-ment of recurrent retinopathy of prematurity after intravitreal bev-acizumab monotherapy. Ophthalmology. 2016; 123:1845–55.

20. Yetik H, Gunay M, Sirop S, Salihoglu Z. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol. 2015; 253:1677–83.

21. Hartnett ME. Pathophysiology and mechanisms of severe retinop-athy of prematurity. Ophthalmology. 2015; 122:200–10.

22. Hoerster R, Muether P, Dahlke C. . Serum concentrations of vascular endothelial growth factor in an infant treated with ranibi-zumab for retinopathy of prematurity. Acta Ophthalmol. 2013; 91:e74–5.

23. Klufas MA, Chan RV. Intravitreal anti-VEGF therapy as a treat-ment for retinopathy of prematurity: what we know after 7 years. J Pediatr Ophthalmol Strabismus. 2015; 52:77–84.

24. Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bev-acizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2008; 246:1061–3.

25. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011; 56:95–113.